Yttrium Y 90-DOTA-tyr3-octreotide
A radiopharmaceutical used in cancer treatment
Yttrium Y 90-DOTA-tyr3-octreotide is a radiopharmaceutical used in the treatment of certain types of cancer, particularly neuroendocrine tumors. It is a form of peptide receptor radionuclide therapy (PRRT), which involves targeting cancer cells with a radioactive substance that binds to specific receptors on the tumor cells.
Mechanism of Action[edit | edit source]
Yttrium Y 90-DOTA-tyr3-octreotide works by targeting the somatostatin receptors that are overexpressed on the surface of neuroendocrine tumor cells. The compound consists of the somatostatin analog octreotide, which is linked to the radioactive isotope yttrium-90 via the chelating agent DOTA. When administered intravenously, the compound binds to the somatostatin receptors on the tumor cells, allowing the yttrium-90 to deliver targeted radiation to the tumor, thereby damaging the cancer cells and inhibiting their growth.
Clinical Use[edit | edit source]
Yttrium Y 90-DOTA-tyr3-octreotide is primarily used in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It is often considered for patients whose tumors express somatostatin receptors and who have not responded adequately to other treatments such as surgery or chemotherapy. The treatment is typically administered in cycles, with careful monitoring of the patient's response and potential side effects.
Side Effects[edit | edit source]
Common side effects of Yttrium Y 90-DOTA-tyr3-octreotide include nausea, vomiting, fatigue, and mild bone marrow suppression. More serious side effects can include renal toxicity and liver damage, which necessitate regular monitoring of kidney and liver function during treatment.
Research and Development[edit | edit source]
Research into Yttrium Y 90-DOTA-tyr3-octreotide continues, with studies focusing on optimizing dosing regimens, minimizing side effects, and expanding its use to other types of tumors that express somatostatin receptors. Clinical trials are also exploring combinations of PRRT with other therapeutic modalities to enhance efficacy.
Also see[edit | edit source]
- Radiopharmaceuticals
- Neuroendocrine tumor
- Peptide receptor radionuclide therapy
- Somatostatin receptor
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
